| Olze, Heidi |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 11/25 | 10/26 | | |
| Cho, Seok-Goo |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
Capella, NCT05493800: Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT |
|
|
| Active, not recruiting | 2 | 60 | RoW | MIT-001, normal saline, placebo | MitoImmune Therapeutics | Oral Mucositis, Lymphoma, Multiple Myeloma, Hematologic Cancer | 06/24 | 12/24 | | |
NCT03671850: VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients |
|
|
| Recruiting | 2 | 48 | RoW | VT-EBV-N, Placebo | ViGenCell Inc. | Extranodal NK/T-cell Lymphoma | 12/23 | 06/24 | | |
NCT01357733: Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients |
|
|
| Active, not recruiting | N/A | 53 | RoW | Early interim FDG PET/CT after 1 cycle of R-CHOP | The Catholic University of Korea | Lymphoma, Large B-Cell, Diffuse | 11/17 | 03/23 | | |
|
| Cha, Bong Yun |
| Completed | 4 | 51 | RoW | Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin | Yonsei University | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Type 2 Diabetes, Digestive System Disease, Liver Diseases, Fatty Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Hypoglycemic Agents, Physiological Effects of Drugs, Sodium-Glucose Cotransporter 2 Inhibitors, Pioglitazone, Molecular Mechanisms of Pharmacological Action, Empagliflozin, Thiazolidinediones | 06/22 | 06/22 | | |
ENVELOP, NCT06642623: A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients |
|
|
| Recruiting | 4 | 2862 | RoW | Enavogliflozin, Dapagliflozin or Empagliflozin | Yonsei University | Diabetes Mellitus, Type 2, Cardiovascular Diseases, Kidney Diseases | 09/29 | 12/30 | | |
| Ko, Yoon Ho |
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
| Lee, In |
BEAT-UT7, NCT06773845: Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria |
|
|
| Not yet recruiting | 2 | 100 | RoW | TheraSphere, Y90 glass microsphere | Seoul National University Hospital, Boston Scientific Corporation | Hepatocellular Carcinoma (HCC), Radioembolization | 12/27 | 12/29 | | |
NCT04554758: Comparative Analysis Between Sleeve Gastrectomy and Roux-en Y Gastric Bypass in Bariatric Operation |
|
|
| Recruiting | N/A | 400 | RoW | Sleeve gastrectomy, Roux-en-Y gastric bypass | Inha University Hospital, Korean Center for Disease Control and Prevention | Obesity, Morbid, Overnutrition, Nutrition Disorders, Overweight and Obesity, Body Weight Changes | 08/22 | 08/23 | | |
NCT04553783: Exploration of Blood Biomarkers, Including Whole Blood Viscosity as a Prognostic Factor for Acute Pancreatitis |
|
|
| Recruiting | N/A | 137 | RoW | | In Seok Lee | Acute Pancreatitis | 05/22 | 05/23 | | |
| Hong |
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin |
|
|
| Recruiting | 3 | 190 | Japan, US, RoW | Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM | CG Oncology, Inc. | Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer | 12/27 | 12/29 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
NCT06127368: Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers |
|
|
| Recruiting | 1 | 56 | RoW | GB-5001A, GB-5001D, Oral cohort | G2GBio, Inc. | Alzheimer Disease | 09/24 | 01/25 | | |
NCT05508100: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors |
|
|
| Completed | 1 | 38 | RoW | IO-108, IO-108 + pembrolizumab, IO-108 + Keytruda®, IO-108 + tislelizumab | Immune-Onc Therapeutics | Advanced Solid Tumor | 04/24 | 04/24 | | |
NCT06734858: Pivotal Trial of SAT-014 for Trauma and Stressor-Related Disorder Symptoms |
|
|
| Recruiting | N/A | 110 | RoW | SAT014, Control | S-Alpha Therapeutics, Inc. | Post-traumatic Stress Disorder, Adjustment Disorders | 07/25 | 10/25 | | |
| Orvain, Corentin |
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms |
|
|
| Recruiting | 3 | 1308 | Europe | Direct Oral Anticoagulants, Low-dose aspirin | University Hospital, Brest | Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients | 07/27 | 07/27 | | |
NCT05753384: Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System |
|
|
| Recruiting | 3 | 140 | Europe | treatment of TKI in CML | Poitiers University Hospital | Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia | 12/28 | 12/29 | | |
| Recruiting | 1/2 | 70 | Europe, Canada, Japan, US, RoW | DSP-5336 | Sumitomo Pharma America, Inc. | Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | 01/25 | 02/25 | | |
BioScoreSMP, NCT03869476: Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. |
|
|
| Completed | N/A | 133 | Europe | Non-invasive diagnosis score | University Hospital, Angers | Myeloproliferative Disorder, Essential Thrombocythemia, Primary Myelofibrosis, Prefibrotic Stage, Primary Myelofibrosis, Fibrotic Stage | 01/24 | 01/24 | | |
PHEMOP, NCT06361641: Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes |
|
|
| Recruiting | N/A | 50 | Europe | Monocytes signatures in myeloproliferative neoplasms at diagnosis | University Hospital, Angers | Myeloproliferative Neoplasm, Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis | 10/25 | 10/27 | | |
NCT06377579: OBServatory of Compassionate Use of IVOsidenib in France for Patients with Acute Myeloid Leukemia |
|
|
| Recruiting | N/A | 250 | Europe | | French Innovative Leukemia Organisation, Acute Leukemia French Association | AML, Adult | 12/24 | 03/25 | | |
ALHERT, NCT06409767: Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. |
|
|
| Not yet recruiting | N/A | 2224 | Europe | Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7. | University Hospital, Angers | Leukemia, Lymphoma, Multiple Myeloma | 10/27 | 01/28 | | |
ADNEMIA, NCT06075888: Metagenomic Sequencing for the Identification of Pathogens in Febrile Neutropenic Patients |
|
|
| Recruiting | N/A | 200 | Europe | Metagenomic diagnosis (mNGS, DISQVER) | Poitiers University Hospital, Noscendo | Immunodepressed Patients (Hemato-oncology) | 01/25 | 01/25 | | |
| Not yet recruiting | N/A | 50 | Europe | Clonal architecture determination | University Hospital, Angers | Myelofibrosis | 03/25 | 03/29 | | |
MOLAM, NCT04931992: Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse. |
|
|
| Recruiting | N/A | 100 | Europe | No intervention | University Hospital, Angers | Acute Myeloid Leukemia | 12/21 | 12/21 | | |
| Choo, Eunho |
NCT06041529: Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension |
|
|
| Recruiting | 4 | 250 | RoW | Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Truset 40/5/12.5mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg, Twynsta 40/5 mg, Dichlozid 25 mg | Yuhan Corporation | Essential Hypertension | 06/25 | 10/25 | | |
